Springbok Analytics said its MRI-based muscle analysis AI software will be used to assess a new treatment for facioscapulohumeral muscular dystrophy (FSHD).
The software is designed to help researchers understand and identify disease progression of FSHD by providing individual MRI muscle volume and fat fraction metrics in trial participants, the company said. The software will be used in a phase I dose escalation study assessing the safety and tolerability of clenbuterol, which has demonstrated improved strength or function in patients in several small studies, the company said.
There are currently no therapies approved by the U.S. Food and Drug Administration for FSHD, a progressive muscle degeneration disorder primarily affecting the muscles of the face, shoulder blades, and upper arms, Springbok noted.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
